Chimeric antigen receptor -T cell therapy (CAR-T cell therapy) is a cancer treatment that shows remarkable clinical responses in hematologic malignancies. The FDA first approved CAR-T for adult commercial use in October of 2017. It was approved to treat two types of blood cancers: aggressive B cell non-Hodgkin lymphoma in adults and B cell acute … Continue reading Car-T Cell Therapy →